LH / Labcorp Holdings Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Labcorp to Speak at the Morgan Stanley 23rd Annual Global Healthcare Conference

FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O’Donnell Media@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 27, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 27, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S

Subsidiary Issuers of Guaranteed Securities

Exhibit 22.1 Subsidiary Issuers of Guaranteed Securities Guaranteed Securities The following securities (collectively referred to in this exhibit as the “Senior Notes”) issued by Laboratory Corporation of America Holdings (“LCAH”), a Delaware corporation and wholly-owned subsidiary of Labcorp Holdings Inc. (“LHI”), a Delaware corporation, were outstanding as of June 30, 2025. Description of Senior

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-11353 LABCORP HOLDINGS INC. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 24, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 24, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S.

Labcorp Announces 2025 Second Quarter Results Raises Full-Year Guidance

FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O’Donnell Media@labcorp.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 9, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. E

Labcorp Declares Quarterly Dividend

FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin O’Donnell Media@Labcorp.

d and Restated Credit Agreement dated as of June 27, 2025, (originally dated as of April 30, 2021), among the Company, Bank of America, N.A., as administrative agent, and lenders party thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed

Exhibit 10.1 Execution Version Exhibit A Deal CUSIP: 50540QAU8 Facility CUSIP: 50540QAV6 FOURTH AMENDED AND RESTATED CREDIT AGREEMENT Dated as of June 27, 2025 (Originally dated as of December 21, 2011, amended and restated as of December 19, 2014, further amended as of July 13, 2016, further amended and restated as of September 15, 2017, further amended as of May 7, 2020, further amended and rest

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 27, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 26, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S.

Labcorp to Announce Second Quarter Financial Results on July 24, 2025

FOR IMMEDIATE RELEASE Media Investor Relations Neil Hirsch Christin O’Donnell Media@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report LABCORP HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of (Co

SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report LABCORP HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 358 South Main Street, Burlington, North Carolina 27215 (

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Labcorp Holdings Inc.

As filed with the Securities and Exchange Commission on May 29, 2025

As filed with the Securities and Exchange Commission on May 29, 2025 Registration No.

As filed with the Securities and Exchange Commission on May 29, 2025

As filed with the Securities and Exchange Commission on May 29, 2025 Registration No.

Power of Attorney.

EX-24.1 Exhibit 24.1 LABCORP HOLDINGS INC. S- 8 Power of Attorney KNOW ALL BY THESE PRESENTS, that each of the undersigned officers and directors of Labcorp Holdings Inc., a Delaware corporation (the “Corporation”), hereby constitutes and appoints Adam H. Schechter, Julia A. Wang and Sandra D. van der Vaart, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full po

Labcorp Holdings Inc. 2025 Employee Stock Purchase Plan

LABCORP HOLDINGS INC. 2025 EMPLOYEE STOCK PURCHASE PLAN Effective May 15, 2025 1.PURPOSE AND INTERPRETATION (a)The purpose of the Plan is to encourage and to enable Eligible Employees of the Company and its Participating Affiliates, through after-tax payroll deductions or periodic cash contributions, to acquire proprietary interests in the Company through the purchase and ownership of shares of St

Labcorp Holdings Inc. 2025 Omnibus Incentive Plan

LABCORP HOLDINGS INC. 2025 OMNIBUS INCENTIVE PLAN 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 8 3.1 Committee 8 3.1.1 Powers and Authorities 8 3.1.2 Composition of the Committee 8 3.1.3 Other Committees 8 3.1.4 Delegation by the Committee 9 3.2 Board 9 3.3 Terms of Awards 9 3.3.1 Committee Authority 9 3.3.2 Forfeiture; Recoupment 10 3.4 No Repricing 10 3.5 Deferral Arrangement 10 3

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 15, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. E

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 8, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. Em

Labcorp to Webcast Its Annual Meeting of Shareholders May 15

Media Investors Neil Hirsch Christin O’Donnell [email protected] [email protected] Labcorp to Webcast Its Annual Meeting of Shareholders May 15 BURLINGTON, N.C., May 8, 2025 – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that its Annual Meeting of Shareholders will be webcast live on May 15 at 9:00 a.m. ET and can be viewed online on t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 29, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 29, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-11353 LABCORP HOLDINGS INC. (

Labcorp Announces 2025 First Quarter Results Updates Full-Year Guidance

FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin Odonnell Media@labcorp.

ubsidiary Issuers of Guaranteed Secu

Exhibit 22.1 Subsidiary Issuers of Guaranteed Securities Guaranteed Securities The following securities (collectively referred to in this exhibit as the “Senior Notes”) issued by Laboratory Corporation of America Holdings (“LCAH”), a Delaware corporation and wholly-owned subsidiary of Labcorp Holdings Inc. (“LHI”), a Delaware corporation, were outstanding as of March 31, 2025. Description of Senio

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 9, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S.

Labcorp Declares Quarterly Dividend

FOR IMMEDIATE RELEASE Media Investors [email protected] [email protected] Labcorp Declares Quarterly Dividend BURLINGTON, N.C., April 10, 2025 - Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on June 11,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  ☒        Filed by a party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant   ☒      Filed by a party other than the Registrant   ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 31, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S.

Labcorp to Announce First Quarter Financial Results on April 29, 2025

FOR IMMEDIATE RELEASE Media Investor Relations Neil Hirsch Nickolo Russo Media@Labcorp.

Power of Attorney of Kirsten M. Kliphouse

Exhibit 24.4 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Sandra D. van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Labcorp Holdings Inc. (Corporation) Annual Report on Form 10-K for the year ended December 31, 2024, under the Securities Ex

List of Subsidiaries of the Company

Exhibit 21.1 LIST OF SUBSIDIARIES 3065619 Nova Scotia Company Accupath Diagnostic Laboratories, Inc. CannAmm OTS Limited Partnership Center For Disease Detection, LLC Clearstone Holdings (International) Ltd. Czura Thornton (Hong Kong) Limited D.H.G. Place du Centre Clinique Ltee. Dianon Systems, Inc. DL Holdings Limited Partnership Dynacare Company Dynacare Northwest Inc. Dynacare Valley Medical L

Power of Attorney of Kerrii B. Anderson

Exhibit 24.1 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Sandra D. van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Labcorp Holdings Inc. (Corporation) Annual Report on Form 10-K for the year ended December 31, 2024, under the Securities Ex

Power of Attorney of Paul B. Rothman, M.D.

Exhibit 24.8 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Sandra D. van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Labcorp Holdings Inc. (Corporation) Annual Report on Form 10-K for the year ended December 31, 2024, under the Securities Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 ☐ Transition report pursuant to Secti

Index UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number - 1-11353 LABCORP HOLDINGS INC

Power of Attorney of Kathryn E. Wengel

Exhibit 24.9 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Sandra D. van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Labcorp Holdings Inc. (Corporation) Annual Report on Form 10-K for the year ended December 31, 2024, under the Securities Ex

Insider Trading Policy, revised March 2023

Exhibit 19.1 BUSINESS PRACTICES MANUAL Insider trading policy Policy Number BPM-16 Title Insider Trading Policy Implementation Date June 2001 Updated June 2018, January 2019, November 2021, March 2023 Statement of Policy This Insider Trading Policy (“Policy”) shall apply to all directors, officers and employees (each a “Covered Person” and collectively “Covered Persons”) of Labcorp Holdings Inc.,

Power of Attorney of Richelle P. Parham

Exhibit 24.7 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Sandra D. van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Labcorp Holdings Inc. (Corporation) Annual Report on Form 10-K for the year ended December 31, 2024, under the Securities Ex

Subsidiary Issuers of Guaranteed Securities

Exhibit 22.1 Subsidiary Issuers of Guaranteed Securities Guaranteed Securities The following securities (collectively referred to in this exhibit as the “Senior Notes”) issued by Laboratory Corporation of America Holdings (“LCAH”), a Delaware corporation and wholly owned subsidiary of Labcorp Holdings Inc. (“LHI”), a Delaware corporation, were outstanding as of December 31, 2024. Description of Se

Power of Attorney of Peter M. Neupert

Exhibit 24.6 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Sandra D. van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Labcorp Holdings Inc. (Corporation) Annual Report on Form 10-K for the year ended December 31, 2024, under the Securities Ex

Power of Attorney of Garheng Kong, M.D., Ph.D.

Exhibit 24.5 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Sandra D. van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Labcorp Holdings Inc. (Corporation) Annual Report on Form 10-K for the year ended December 31, 2024, under the Securities Ex

Aircraft Time Sharing Agreement by and between Laboratory Corporation of America Holdings and Adam H. Schechter on November 18, 2024.

Exhibit 10.25 AIRCRAFT TIME SHARING AGREEMENT This Aircraft Time Sharing Agreement (the "Agreement") is made and entered into as of this 18th day of November 2024, by and between Laboratory Corporation of America Holdings (“Company”), and Adam H. Schechter, an individual (“Lessee”), who together are sometimes also referred to herein individually as a "Party" or collectively as the "Parties." WITNE

Power of Attorney of D. Gary Gilliland, M.D., Ph.D.

Exhibit 24.3 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Sandra D. van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Labcorp Holdings Inc. (Corporation) Annual Report on Form 10-K for the year ended December 31, 2024, under the Securities Ex

Power of Attorney of Jeffrey A. Davis

Exhibit 24.2 POWER OF ATTORNEY The undersigned hereby constitutes and appoints Sandra D. van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Labcorp Holdings Inc. (Corporation) Annual Report on Form 10-K for the year ended December 31, 2024, under the Securities Ex

Labcorp Announces 2024 Fourth Quarter and Full Year Results Company Provides 2025 Guidance

FOR IMMEDIATE RELEASE Media Investors [email protected] [email protected] Labcorp Announces 2024 Fourth Quarter and Full Year Results Company Provides 2025 Guidance •Results from Continuing Operations versus last year: ◦Revenue: Q4 of $3.33 billion vs $3.03 billion; Full year of $13.01 billion vs $12.16 billion ◦Diluted EPS: Q4 of $1.70 vs $(1.95); Full year of $8.84 vs $4.33 ◦Adjusted EPS: Q4

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 6, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 31, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.

First Amendment to Receivables Purchase Agreement dated as of January 31, 2025

Exhibit 10.1 EXECUTION VERSION FIRST AMENDMENT TO THE RECEIVABLES PURCHASE AGREEMENT This FIRST AMENDMENT TO THE RECEIVABLES PURCHASE AGREEMENT (this “Amendment”), dated as of January 31, 2025, is entered into by and among the following parties: (i)LABCORP RECEIVABLES LLC, a Delaware limited liability company, as Seller (the “Seller”); (ii)LABORATORY CORPORATION OF AMERICA HOLDINGS, a Delaware cor

LABCORP DECLARES QUARTERLY DIVIDEND

FOR IMMEDIATE RELEASE Media Investors [email protected] [email protected] LABCORP DECLARES QUARTERLY DIVIDEND BURLINGTON, N.C., January 8, 2025 - Labcorp Holdings Inc.(NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock. The dividend will be payable on March 12

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 10, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.

Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference

FOR IMMEDIATE RELEASE Media Investors [email protected] [email protected] Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference BURLINGTON, N.C., (January 10, 2025) — Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that members of the executive management team will participate in a fireside chat at the 43rd A

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 8, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 8, 2025 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S

Labcorp to Announce Fourth Quarter Financial Results on February 6, 2025

FOR IMMEDIATE RELEASE Media Investors [email protected] [email protected] Labcorp to Announce Fourth Quarter Financial Results on February 6, 2025 BURLINGTON, N.C., Jan. 8, 2025 – Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fourth quarter of 2024 before the market opens on Thursday, February 6,

Labcorp CFO Glenn Eisenberg Announces Plans to Retire Julia Wang Named Chief Financial Officer Beginning December 2, 2024

FOR IMMEDIATE RELEASE Contact: Christin O’Donnell (investors) [email protected] Kimbrel Arculeo (media) [email protected] Labcorp CFO Glenn Eisenberg Announces Plans to Retire Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C, November 19, 2024 – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that Execut

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 15, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11353 LABCORP HOLDINGS IN

Subsidiary Issuers of Guaranteed Securities

Exhibit 22.1 Subsidiary Issuers of Guaranteed Securities Guaranteed Securities The following securities (collectively referred to in this exhibit as the “Senior Notes”) issued by Laboratory Corporation of America Holdings (“LCAH”), a Delaware corporation and wholly-owned subsidiary of Labcorp Holdings Inc. (“LHI”), a Delaware corporation, were outstanding as of September 30, 2024. Description of S

Labcorp Announces 2024 Third Quarter Results Updates Full-Year Guidance

FOR IMMEDIATE RELEASE Contact: Christin O'Donnell (investors) [email protected] Kimbrel Arculeo (media) [email protected] Labcorp Announces 2024 Third Quarter Results Updates Full-Year Guidance •Results from Continuing Operations for third quarter 2024 versus last year: ◦Revenue: $3.28 billion versus $3.06 billion ◦Diluted EPS: $2.00 versus $2.11 ◦Adjusted EPS: $3.50 versus $3.38 ◦Free Cash Flo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 24, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Nam

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 24, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 9, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S

Labcorp Declares Quarterly Dividend

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Christin O'Donnell — 336-436-5076 Investor@Labcorp.

Labcorp to Announce Third Quarter Financial Results on October 24, 2024

FOR IMMEDIATE RELEASE Labcorp Contacts: Media Investors Kimbrel Arculeo Christin O'Donnell 336-436-8263 336-436-5076 Media@Labcorp.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 24, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.

Second Supplemental Indenture, dated as of September 23, 2024, among Laboratory Corporation of America Holdings, as issuer, Labcorp Holdings Inc., as guarantor, and U.S. Bank Trust Company, National Association, as trustee, including the form of the 2032 Notes

Exhibit 4.3 $500,000,000 4.550% SENIOR NOTES DUE 2032 LABORATORY CORPORATION OF AMERICA HOLDINGS as Issuer AND LABCORP HOLDINGS INC. as Guarantor AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee SECOND SUPPLEMENTAL INDENTURE DATED AS OF September 23, 2024 TABLE OF CONTENTS PAGE ARTICLE 1 RELATION TO INDENTURE; DEFINITIONS; RULES OF CONSTRUCTION Section 1.01. Scope of Supplemental Inden

Indenture, dated as of September 23, 2024, between Laboratory Corporation of America Holdings, as issuer, and U.S. Bank Trust Company, National Association, as trustee

Exhibit 4.1 LABORATORY CORPORATION OF AMERICA HOLDINGS, as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE DATED AS OF SEPTEMBER 23, 2024 SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as Amended Indenture 310(a) Section 7.10 310(b) Section 7.08; Section 7.10 310(c) Inapplicable 311(a) Section 7.11 311(b) Section 7.11 311(c) Ina

Third Supplemental Indenture, dated as of September 23, 2024, among Laboratory Corporation of America Holdings, as issuer, Labcorp Holdings Inc., as guarantor, and U.S. Bank Trust Company, National Association, as trustee, including the form of the 2034 Notes

Exhibit 4.4 $850,000,000 4.800% SENIOR NOTES DUE 2034 LABORATORY CORPORATION OF AMERICA HOLDINGS as Issuer AND LABCORP HOLDINGS INC. as Guarantor AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee THIRD SUPPLEMENTAL INDENTURE DATED AS OF September 23, 2024 TABLE OF CONTENTS PAGE ARTICLE 1 RELATION TO INDENTURE; DEFINITIONS; RULES OF CONSTRUCTION Section 1.01. Scope of Supplemental Indent

First Supplemental Indenture, dated as of September 23, 2024, among Laboratory Corporation of America Holdings, as issuer, Labcorp Holdings Inc., as guarantor, and U.S. Bank Trust Company, National Association, as trustee, including the form of the 2030 Notes

Exhibit 4.2 $650,000,000 4.350% SENIOR NOTES DUE 2030 LABORATORY CORPORATION OF AMERICA HOLDINGS as Issuer AND LABCORP HOLDINGS INC. as Guarantor AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE DATED AS OF September 23, 2024 TABLE OF CONTENTS PAGE ARTICLE 1 RELATION TO INDENTURE; DEFINITIONS; RULES OF CONSTRUCTION Section 1.01. Scope of Supplemental Indent

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 LABCORP HOLDINGS INC. (Exact name of registrant as specified in Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of incorporation) (Commission File

LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $500,000,000 IN 4.550% SENIOR NOTES DUE 2032 AND $850,000,000 IN 4.800% SENIOR NOTES DUE 2034

Exhibit 99.1 FOR IMMEDIATE RELEASE Labcorp Contacts: Media: Kimbrel Arculeo — 336-436-8263 [email protected] Investors: Christin O’Donnell — 336-436-5076  [email protected] LABCORP PRICES $650,000,000 IN 4.350% SENIOR NOTES DUE 2030, $500,000,000 IN 4.550% SENIOR NOTES DUE 2032 AND $850,000,000 IN 4.800% SENIOR NOTES DUE 2034 BURLINGTON, N.C., September 16, 2024 — Labcorp Holdings Inc. (NYSE:LH

Underwriting Agreement, dated September 16, 2024, by and among Labcorp Holdings Inc., Laboratory Corporation of America Holdings, BofA Securities, Inc., U.S. Bancorp Investments, Inc., and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein

Exhibit 1.1 Execution Version Labcorp Holdings Inc. Laboratory Corporation of America Holdings $650,000,000 4.350% Senior Notes due 2030 $500,000,000 4.550% Senior Notes due 2032 $850,000,000 4.800% Senior Notes due 2034 Underwriting Agreement New York, New York September 16, 2024 To the Representatives named in Schedule I hereto of the several Underwriters named in Schedule II hereto Ladies and G

$2,000,000,000 Laboratory Corporation of America Holdings $650,000,000 4.350% Senior Notes due 2030 $500,000,000 4.550% Senior Notes due 2032 $850,000,000 4.800% Senior Notes due 2034 Fully and Unconditionally Guaranteed by Labcorp Holdings Inc.

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279510 Registration No. 333-279510-01 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 17, 2024) $2,000,000,000 Laboratory Corporation of America Holdings $650,000,000 4.350% Senior Notes due 2030 $500,000,000 4.550% Senior Notes due 2032 $850,000,000 4.800% Senior Notes due 2034 Fully and Unconditionally Guaranteed by Labcorp H

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2024 LABCORP HOLDINGS INC. (Exact name of registrant as specified in Charter) Delaware (Labcorp Holdings Inc.) 1-11353 99-2588107 (State or other jurisdiction of incorpo

Calculation of Filing Fee Tables (Form Type) Laboratory Corporation of America Holdings Labcorp Holdings Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Laboratory Corporation of America Holdings Labcorp Holdings Inc.

SUBJECT TO COMPLETION, DATED SEPTEMBER 16, 2024

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-279510 Registration No. 333-279510-01 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and they are not soliciting an offer to buy these securities in any jurisdict

PRICING TERM SHEET LABORATORY CORPORATION OF AMERICA HOLDINGS Fully and unconditionally guaranteed by Labcorp Holdings Inc. September 16, 2024 $650,000,000 4.350% Senior Notes due 2030 $500,000,000 4.550% Senior Notes due 2032 $850,000,000 4.800% Sen

Filed Pursuant to Rule 433 Registration Nos. 333-279510 and 333-279510-01 Issuer Free Writing Prospectus dated September 16, 2024 Relating to Preliminary Prospectus Supplement dated September 16, 2024 PRICING TERM SHEET LABORATORY CORPORATION OF AMERICA HOLDINGS Fully and unconditionally guaranteed by Labcorp Holdings Inc. September 16, 2024 $2,000,000,000 $650,000,000 4.350% Senior Notes due 2030

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 3, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R

Labcorp to Speak at the Baird 2024 Global Healthcare Conference

FOR IMMEDIATE RELEASE LabCorp Contacts: Media: Kimbrel Arculeo – 336-436-8263 Media@Labcorp.

Performance Guaranty, dated as August 23, 2024, by Labcorp Holdings, Inc., in favor of PNC Bank National Association, as administrative agent (incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on August 23, 2024)

Exhibit 10.3 EXECUTION VERSION PERFORMANCE GUARANTY This PERFORMANCE GUARANTY (as amended, supplemented or otherwise modified from time to time, this “Performance Guaranty”), dated as of August 23, 2024, is made by LABCORP HOLDINGS INC., a Delaware corporation (the “Performance Guarantor”), in favor of PNC BANK, NATIONAL ASSOCIATION (“PNC”), as administrative agent under the Receivables Purchase A

Sale and Contribution Agreement, dated as of August 23, 2024, by and among each of the persons from time to time party hereto, as originators, Laboratory Corporation of America Holdings, as an originator and as servicer, and Labcorp Receivable LLC, as buyer (incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on August 23, 2024)

Exhibit 10.2 EXECUTION VERSION SALE AND CONTRIBUTION AGREEMENT Dated as of August 23, 2024 among EACH OF THE PERSONS FROM TIME TO TIME PARTY HERETO, as Originators, LABORATORY CORPORATION OF AMERICA HOLDINGS as an Originator and as Servicer, and LABCORP RECEIVABLES LLC, as Buyer CONTENTS Clause Subject Matter Page ARTICLE I SALES AND CONTRIBUTIONS...................................................

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 23, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S

Receivables Purchase Agreement dated as of August 23, 2024

Exhibit 10.1 EXECUTION VERSION RECEIVABLES PURCHASE AGREEMENT Dated as of August 23, 2024 by and among LABCORP RECEIVABLES LLC, as Seller, THE PERSONS FROM TIME TO TIME PARTY HERETO, as Purchasers, PNC BANK, NATIONAL ASSOCIATION, as Administrative Agent, LABORATORY CORPORATION OF AMERICA HOLDINGS, as Servicer, and PNC CAPITAL MARKETS LLC, as Structuring Agent TABLE OF CONTENTS Page ARTICLE I DEFIN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11353 LABCORP HOLDINGS INC. (E

Subsidiary Issuers of Guaranteed Securities

EX-22.1 2 ex221q22024.htm EX-22.1 Exhibit 22.1 Subsidiary Issuers of Guaranteed Securities Guaranteed Securities The following securities (collectively referred to in this exhibit as the “Senior Notes”) issued by Laboratory Corporation of America Holdings (“LCAH”), a Delaware corporation and wholly-owned subsidiary of Labcorp Holdings Inc. (“LHI”), a Delaware corporation, were outstanding as of Ju

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 01, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S

Labcorp Announces 2024 Second Quarter Results Updates Full-Year Guidance

FOR IMMEDIATE RELEASE Contact: Christin O'Donnell (investors) – 336-436-5076 Investor@Labcorp.

LABCORP DECLARES QUARTERLY DIVIDEND

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Christin O'Donnell — 336-436-5076 Investor@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 24, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 24, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S.

Labcorp to Announce Second Quarter Financial Results on August 1, 2024

FOR IMMEDIATE RELEASE Labcorp Contacts: Media Investors Kimbrel Arculeo Christin O'Donnell 336-436-8263 336-436-5076 Media@Labcorp.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 1, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 4, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 4, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. E

©2024 Labcorp. All rights reserved. Labcorp: Executing on Growth Strategy J U N E 2 0 2 4 2 ©2024 Labcorp. All rights reserved. Cautionary statement regarding forward-looking statements This presentation contains forward-looking statements, including

lh2024wbpresentation ©2024 Labcorp. All rights reserved. Labcorp: Executing on Growth Strategy J U N E 2 0 2 4 2 ©2024 Labcorp. All rights reserved. Cautionary statement regarding forward-looking statements This presentation contains forward-looking statements, including, but not limited to, statements with respect to (i) the estimated 2024 guidance and related assumptions, (ii) the recently compl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number : 1-11353 Laboratory Corporation of America Holdings (Exact name of registra

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report LABCORP HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of (Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report LABCORP HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 358 South Main Street, Burlington, North Carolina 27215 (Add

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 28, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 28, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. E

Labcorp to Speak at the 44th Annual William Blair Growth Stock Conference

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Christin O'Donnell — 336-436-5076 Investor@Labcorp.

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on May 31, 2024, pursuant to the provisions of Rule 12d2-2 (a).

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Labcorp Holdings Inc.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

Labcorp Holdings Inc. Amended and Restated 2016 Employee Stock Purchase Plan.

Exhibit 10.5 LABCORP HOLDINGS INC. AMENDED AND RESTATED 2016 EMPLOYEE STOCK PURCHASE PLAN As Amended and Restated, Effective May 17, 2024 1. PURPOSE AND INTERPRETATION (a) The purpose of the Plan is to encourage and to enable Eligible Employees of the Company and its Participating Affiliates, through after-tax payroll deductions or periodic cash contributions, to acquire proprietary interests in t

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

New Holding Company Guarantee, dated May 17, 2024, by Labcorp Holdings Inc.

Exhibit 4.3 NEW HOLDING COMPANY GUARANTEE From and after the date hereof, Labcorp Holdings Inc., a Delaware corporation (“New Holding Company”), unconditionally and irrevocably guarantees (the “Guarantee”) to each Securityholder of a Security authenticated and delivered by the Trustee, and to the Trustee and its successors and assigns, the due and punctual payment of the principal of, premium, if

Assignment and Assumption Agreement, dated as of May 17, 2024, by and among Laboratory Corporation of America Holdings, Labcorp Holdings Inc. and Adam H. Schechter (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K12B filed on May 17, 2024).

Exhibit 10.2 ASSIGNMENT AND ASSUMPTION AGREEMENT This Assignment and Assumption Agreement (this “Agreement”) is entered into this 17th day of May, 2024 by and between Laboratory Corporation of America Holdings (“Labcorp”), Labcorp Holdings Inc. (“LHI”) and Adam H. Schechter (“Executive”). RECITALS WHEREAS, Labcorp and Executive have previously entered into an Executive Employment Agreement as of J

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

Form 8-K12B

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 17, 2024 (Date of earliest event reported) LABCORP HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 99-2588107 (State or other jurisdiction of Incorporation) (Commission File Number) (I.R.S. E

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

Labcorp Holdings Inc. Amended and Restated 2016 Omnibus Incentive Plan.

Exhibit 10.4 LABCORP HOLDINGS INC. AMENDED AND RESTATED 2016 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 8 3.1 Committee 8 3.1.1 Powers and Authorities 8 3.1.2 Composition of the Committee 9 3.1.3 Other Committees 9 3.1.4 Delegation by the Committee. 9 3.2 Board 10 3.3 Terms of Awards 10 3.3.1 Committee Authority 10 3.3.2 Forfeiture; Re

Form of Senior Indenture.*

EX-4.02 Exhibit 4.02 LABORATORY CORPORATION OF AMERICA HOLDINGS, as Issuer AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE DATED AS OF [●], 20[●] SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as Amended Indenture 310(a) 7.10 310(b) 7.08; 7.10 310(c) Inapplicable 311(a) 7.11 311(b) 7.11 311(c) Inapplicable 312(a) 2.12; 2.13(a) 312(b) 2

Consent of Hogan Lovells US LLP (included in Exhibit 5.01).*

EX-5.01 Exhibit 5.1 Hogan Lovells US LLP Harbor East 100 International Drive Suite 2000 Baltimore, MD 21202 T +1 410 659 2700 F +1 410 659 2701 www.hoganlovells.com May 17, 2024 Board of Directors Labcorp Holdings Inc. 358 South Main Street Burlington, North Carolina 27215 Board of Directors Laboratory Corporation of America Holdings 358 South Main Street Burlington, North Carolina 27215 To the ad

Amended and Restated By-laws of Labcorp Holdings Inc.

Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF LABCORP HOLDINGS INC. (hereinafter called the “Corporation”) (as amended as of May 17, 2024) ARTICLE I MEETINGS OF STOCKHOLDERS Section 1. Place of Meetings. Meetings of the stockholders for the election of directors or for any other purpose shall be held at such time and place, either within or without the State of Delaware, as shall be designated from

Agreement and Plan of Merger, dated May 17, 2024, by and among Laboratory Corporation of America Holdings, Labcorp Holdings Inc. and Radiance Merger Sub Inc.

Exhibit 2.1 AGREEMENT AND PLAN OF MERGER This AGREEMENT AND PLAN OF MERGER (the “Agreement”), entered into as of May 17, 2024, by and among Laboratory Corporation of America Holdings, a Delaware corporation (the “Company”), Labcorp Holdings Inc., a Delaware corporation (“New Parent”) and a direct, wholly owned subsidiary of the Company, and Radiance Merger Sub Inc., a Delaware corporation (“Merger

Amended and Restated Certificate of Incorporation of Laboratory Corporation of America Holdings (incorporated by reference herein to Exhibit 3.3 to the Company’s Current Report on Form 8-K filed on May 17, 2024).

Exhibit 3.3 CERTIFICATE OF MERGER OF RADIANCE MERGER SUB INC. (a Delaware corporation) WITH AND INTO LABORATORY CORPORATION OF AMERICA HOLDINGS (a Delaware corporation) Pursuant to Section 251 of the General Corporation Law of the State of Delaware (the “DGCL”), the undersigned corporation does hereby certify the following information in connection with the merger (the “Merger”) of Radiance Merger

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

Powers of Attorney.*

EX-24.01 Exhibit 24.1 LABORATORY CORPORATION OF AMERICA HOLDINGS S-3 Power of Attorney KNOW ALL BY THESE PRESENTS, that each of the undersigned officers and directors of Laboratory Corporation of America Holdings, a Delaware corporation (the “Corporation”), hereby constitutes and appoints Adam H. Schechter, Glenn A. Eisenberg and Sandra D. van der Vaart, and each of them, as his or her true and la

Power of Attorney.

Exhibit 24.1 LABCORP HOLDINGS INC. S- 8 Power of Attorney KNOW ALL BY THESE PRESENTS, that each of the undersigned officers and directors of Labcorp Holdings Inc., a Delaware corporation (the “Corporation”), hereby constitutes and appoints Adam H. Schechter, Glenn A. Eisenberg and Sandra D. van der Vaart, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

Exhibit 4.1

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Labcorp Holdings Inc. (“we” and “our”) has only one class of securities of registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, $0.10 par value per share (“Common Stock”). DESCRIPTION OF COMMON STOCK The following description o

Amended and Restated By-Laws of Laboratory Corporation of America Holdings.*

EX-3.04 Exhibit 3.04 AMENDED AND RESTATED BY-LAWS OF LABORATORY CORPORATION OF AMERICA HOLDINGS (hereinafter called the “Corporation”) (as amended and restated as of May 17, 2024) 1. OFFICES 1.1 Registered Office The initial registered office of the Corporation in the State of Delaware shall be at 251 Little Falls Drive in the City of Wilmington, County of New Castle, Delaware 19808. The name of t

Form of Subordinated Indenture.*

EX-4.04 Exhibit 4.04 LABORATORY CORPORATION OF AMERICA HOLDINGS, as Issuer AND [       ], as Trustee INDENTURE DATED AS OF [    ], 202[ ] SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as Amended Indenture 310(a) 7.10 310(b) 7.08; 7.10 310(c) Inapplicable 311(a) 7.11 311(b) 7.11 311(c) Inapplicable 312(a) 5.01; 5.02(a) 312(b) 5.02(c) 312(c) Inapplicable

Statement of Eligibility of Trustee on Form T-1.*

EX-25.01 Exhibit 25.01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its char

Amended and Restated Certificate of Incorporation of Labcorp Holdings Inc.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LABCORP HOLDINGS INC. Pursuant to Sections 242, 245 and 228 of the General General Corporation Law of the State of Delaware * * * * * Labcorp Holdings Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1.The name of the Corporation is Labcorp Holdings I

Consent of Deloitte & Touche LLP.*

EX-23.01 Exhibit 23.01 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement on Form S-3 of our reports dated February 26, 2024, relating to the consolidated financial statements of Laboratory Corporation of America Holdings and the effectiveness of Laboratory Corporation of America Holdings’ internal control over finan

Seventeenth Supplemental Indenture, dated as of May 17, 2024, by and among Laboratory Corporation of America Holdings, as issuer, Labcorp Holdings Inc., as guarantor, and U.S. Bank National Trust Company, Association, as trustee.

Exhibit 4.2 LABORATORY CORPORATION OF AMERICA HOLDINGS as Issuer AND LABCORP HOLDINGS INC. as Guarantor AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee SEVENTEENTH SUPPLEMENTAL INDENTURE DATED AS OF MAY 17, 2024 SEVENTEENTH SUPPLEMENTAL INDENTURE (this “Seventeenth Supplemental Indenture”), dated as of May 17, 2024, among Labcorp Holdings Inc., a Delaware corporation (or its permitted

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 17, 2024

Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 17, 2024 REGISTRATION NO.

Guarantor Joinder Agreement, dated May 17, 2024, by and between Labcorp Holdings Inc. and Bank of America, N.A. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K12B filed on May 17, 2024).

Exhibit 10.1 GUARANTOR JOINDER AGREEMENT May 17, 2024 Reference is made to the Third Amended and Restated Credit Agreement, dated as of April 30, 2021 (as amended, amended and restated, supplemented, waived or otherwise modified from time to time, the “Credit Agreement”) among the Borrower, the Lenders party thereto and Bank of America, N.A., as Administrative Agent. Terms defined in the Credit Ag

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

Assignment and Assumption Agreement, dated as of May 17, 2024, by and among Laboratory Corporation of America Holdings, Labcorp Holdings Inc. and Radiance Merger Sub Inc. (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K12B filed on May 17, 2024).

Exhibit 10.3 ASSIGNMENT AND ASSUMPTION AGREEMENT THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Agreement”) dated as of May 17, 2024 is between Laboratory Corporation of America Holdings, a Delaware corporation (“Labcorp”), Labcorp Holdings Inc., a Delaware corporation (“LHI”), and Radiance Merger Sub Inc., a Delaware corporation (“Merger Sub”). All capitalized terms used in this Agreement and no

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

Filing Fee Table*

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Labcorp Holdings Inc.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

As filed with the Securities and Exchange Commission on May 17, 2024

As filed with the Securities and Exchange Commission on May 17, 2024 Registration No.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 14, 2024 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission F

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 8, 2024 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission Fi

Labcorp to Webcast Its Annual Meeting of Shareholders

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Christin O'Donnell - 336-436-5076 Investor@Labcorp.

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Laboratory Corporation Holdings of America Name of persons relying on exemption: Tara Health Foundation Address of persons relying on exemption: 47 Kearny Street, San Francisco, CA 94108 Written materials are submitted pursuant to Rule 14a-6(g) (1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11353 LABORATORY CORPORATION

Amended and Restated Laboratory Corporation of America Holdings Master Senior Executive Severance Plan

AMENDED AND RESTATED LABORATORY CORPORATION OF AMERICA HOLDINGS MASTER SENIOR EXECUTIVE SEVERANCE PLAN (Effective March 1, 2024) PURPOSE The purpose of this Amended and Restated Laboratory Corporation of America Holdings Master Senior Executive Severance Plan (the “Plan”) is to provide severance benefits for a select group of management employees of Laboratory Corporation of America Holdings.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 25, 2024 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

Labcorp Announces 2024 First Quarter Results Updates Full-Year Guidance

FOR IMMEDIATE RELEASE Contact: Christin O'Donnell (investors) – 336-436-5076 Investor@Labcorp.

LABCORP DECLARES QUARTERLY DIVIDEND

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Christin O'Donnell — 336-436-5076 Investor@Labcorp.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 10, 2024 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

SEC COURTESY COPY

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant  ☒        Filed by a party other than the Registrant  ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant   ☒         Filed by a party other than the Registrant   ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

Labcorp to Announce First Quarter Financial Results on April 25, 2024

FOR IMMEDIATE RELEASE Labcorp Contacts: Media: Kimbrel Arculeo — 336-436-8263 Media@Labcorp.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 27, 2024 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [☒] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 [☐] Transition report pursuant to S

Index UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [☒] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or [☐] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number - 1-11353 LABORATORY CORPO

Power of Attorney of Richelle P. Parham

Exhibit 24.8 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

Amendment to the Laboratory Corporation of America Holdings Am

Exhibit 10.15 SECOND AMENDMENT TO THE LABORATORY CORPORATION OF AMERICA HOLDINGS 2016 EMPLOYEE STOCK PURCHASE PLAN As Amended and Restated Effective January 1, 2022 THIS SECOND AMENDMENT to the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan was made on the 8th day of December, 2023. WHEREAS, Laboratory Corporation of America Holdings, a Delaware corporation (the Compa

Incentive Compensation Recoupment Policy, effective October

Exhibit 97 BUSINESS PRACTICES MANUAL Incentive compensation recoupment policy Policy Number BPM-16.

Power of Attorney of Jeffrey A. Davis

Exhibit 24.3 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

List of Subsidiaries of the Company

Exhibit 21 LIST OF SUBSIDIARIES 1957285 Ontario Inc. 2089729 Ontario, Inc. 2248848 Ontario Inc. 3065619 Nova Scotia Company 3257959 Nova Scotia Company 896988 Ontario Limited 9279-3280 Quebec Inc. Accupath Diagnostic Laboratories, Inc. Beacon Laboratory Benefit Solutions, Inc. BeaconLBS IPA, Inc. CannAmm GP Inc. CannAmm Limited Partnership Center for Disease Detection, LLC Centrex Clinical Laborat

Power of Attorney of Jean-Luc Bélingard

Exhibit 24.2 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

Power of Attorney of R. Sanders Williams, M.D.

Exhibit 24.11 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for

Power of Attorney of D. Gary Gilliland, M.D., Ph.D.

Exhibit 24.4 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

Power of Attorney of Garheng Kong, M.D., Ph.D.

Exhibit 24.6 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

Power of Attorney of Kathryn E. Wengel

Exhibit 24.10 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for

Power of Attorney of

Exhibit 24.11 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for

Power of Attorney of Peter M. Neupert

Exhibit 24.7 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

Power of Attorney of Kirsten M. Kliphouse

Exhibit 24.5 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

Power of Attorney of Kerrii B. Anderson

Exhibit 24.1 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

Labcorp Announces 2023 Fourth Quarter and Full Year Results Company Provides 2024 Guidance

FOR IMMEDIATE RELEASE Contact: Christin O'Donnell (investors) – 336-436-5076 Investor@Labcorp.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 February 15, 2024 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commiss

LH / Laboratory Corporation of America Holdings / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01307-laboratorycorpofamer.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Laboratory Corp of America Holdings Title of Class of Securities: Common Stock CUSIP Number: 50540R409 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appro

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 16, 2024 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commissi

LABCORP TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS ON FEBRUARY 15, 2024

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Christin O’Donnell — 336-436-5076 Investor@Labcorp.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 11, 2024 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commissi

LABCORP DECLARES QUARTERLY DIVIDEND

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Christin O'Donnell — 336-436-5076 Investor@Labcorp.

LABCORP TO SPEAK AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

FOR IMMEDIATE RELEASE LabCorp Contacts: Media: Kimbrel Arculeo – 336-436-8263 Media@Labcorp.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 2, 2024 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commissio

Employment Separation Agreement and General Released effective September 8, 2023, by and Between Laboratory Corporation of America Holdings and Paul Kirchgraber

Exhibit 10.1 September 1, 2023 Paul Kirchgraber 113 W. Lake Court Athens GA 30606 Re: Employment Separation Agreement and General Release Dear Paul, On behalf of Laboratory Corporation of America Holdings and its subsidiary companies (the “Company”), I write to offer you (the “Employee”) the following Employment Separation Agreement and General Release (the “Agreement”) in accordance with the term

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11353 LABORATORY CORPORAT

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 26, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commissi

Labcorp Announces 2023 Third Quarter Results Company Updates Full-Year Guidance

FOR IMMEDIATE RELEASE Contact: Christin O'Donnell (investors) – 336-436-5076 Investor@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 11, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 October 11, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commissi

LABCORP DECLARES QUARTERLY DIVIDEND

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Christin O'Donnell — 336-436-5076 Investor@Labcorp.

LABCORP TO ANNOUNCE THIRD QUARTER FINANCIAL RESULTS ON OCTOBER 26, 2023

FOR IMMEDIATE RELEASE Labcorp Contacts: Christin O'Donnell (investors) — 336-436-5076 Investor@Labcorp.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 29, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commis

©2023 Laboratory Corporation of America® Holdings. All rights reserved. Investor Day September 14, 2023 S E P T E M B E R 2 0 2 3 2©2023 Laboratory Corporation of America® Holdings. All rights reserved. Cautionary statement regarding forward-looking

lhinvestordaynyse ©2023 Laboratory Corporation of America® Holdings. All rights reserved. Investor Day September 14, 2023 S E P T E M B E R 2 0 2 3 2©2023 Laboratory Corporation of America® Holdings. All rights reserved. Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements, including, but not limited to, statements with respect to (i) t

Labcorp to Present Strategy, Business and Financial Outlook at Investor Day

Labcorp Contacts: Christin O'Donnell (investors) — 336-436-5076 [email protected] Kimbrel Arculeo (media) — 336-436-8263 [email protected] Labcorp to Present Strategy, Business and Financial Outlook at Investor Day BURLINGTON, N.C., September 14, 2023 — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, is hosting an Investor Day beginning at 1:00 p.m. ET t

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 14, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commis

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 8, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commiss

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 8, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

Laboratory Corporation of America Holdings Amended and Restated 2016 Employee Stock Purchase Plan

LABORATORY CORPORATION OF AMERICA HOLDINGS 2016 EMPLOYEE STOCK PURCHASE PLAN As Amended and Restated, Effective January 1, 2022 1.

First Amendment to the Laboratory Corporation of America Holdings Amended and Restated 2016 Employee Stock Purchase Plan

FIRST AMENDMENT TO THE LABORATORY CORPORATION OF AMERICA HOLDINGS 2016 EMPLOYEE STOCK PURCHASE PLAN As Amended and Restated Effective January 1, 2022 THIS FIRST AMENDMENT to the Laboratory Corporation of America Holdings 2016 Employee Stock Purchase Plan was made on the 1st day of May, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11353 LABORATORY CORPORATION O

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 31, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 31, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

Labcorp to Host Investor Day on September 14, 2023

FOR IMMEDIATE RELEASE LabCorp Contacts: Christin O'Donnell (investors) – 336-436-5076 Investor@Labcorp.

Labcorp Announces 2023 Second Quarter Results Company Provides Full-Year Guidance

FOR IMMEDIATE RELEASE Contact: Chas Cook (investors) – 336-436-5076 Investor@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 27, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 27, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

ENZ / Enzo Biochem, Inc. / Laboratory Corp Of America Holdings - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Enzo Biochem, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 294100102 (CUSIP Number) Sandra van der Vaart Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary Laboratory

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 12, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 July 12, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

LABCORP DECLARES QUARTERLY DIVIDEND

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Chas Cook — 336-436-5076 Investor@Labcorp.

Laboratory Corporation of America Holdings Unaudited Condensed Consolidated Pro Forma Financial Information

Exhibit 99.1 Laboratory Corporation of America Holdings Unaudited Condensed Consolidated Pro Forma Financial Information The following unaudited condensed consolidated pro forma statements of operations for the three months ended March 31, 2023 and the fiscal years ended December 31, 2022, December 31, 2021 and December 31, 2020 reflect the results of operations as if the spinoff had occurred on J

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 30, 2023 (Date of earliest event reported) LABORATORY CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 30, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorpo

Employee Matters Agreement, dated June 29, 2023, by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

EMPLOYEE MATTERS AGREEMENT BETWEEN LABORATORY CORPORATION OF AMERICA HOLDINGS AND FORTREA HOLDINGS INC.

Separation and Distribution Agreement, dated June 29, 2023, by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

SEPARATION AND DISTRIBUTION AGREEMENT BETWEEN LABORATORY CORPORATION OF AMERICA HOLDINGS AND FORTREA HOLDINGS INC.

Transition Services Agreement, dated June 29, 2023, by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

TRANSITION SERVICES AGREEMENT BETWEEN LABORATORY CORPORATION OF AMERICA HOLDINGS AND FORTREA INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 30, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 30, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

LABCORP COMPLETES SPIN-OFF OF FORTREA

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Chas Cook — 336-436-5076 Investor@Labcorp.

Tax Matters Agreement, dated June 29, 2023, by and between Laboratory Corporation of America Holdings and Fortrea Holdings Inc.

TAX MATTERS AGREEMENT BY AND BETWEEN LABORATORY CORPORATION OF AMERICA HOLDINGS AND FORTREA HOLDINGS INC.

LABCORP TO ANNOUNCE SECOND QUARTER FINANCIAL RESULTS ON JULY 27, 2023

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Chas Cook — 336-436-5076 Investor@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 29, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 12, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 12, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

Labcorp Announces Additional Information in Connection with its Spin-off of Fortrea

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Chas Cook — 336-436-5076 Investor@Labcorp.

Labcorp Announces Pricing of Fortrea $570 Million Notes Offering in Connection With Anticipated Fortrea Spinoff

FOR IMMEDIATE RELEASE Labcorp Contacts: Media: Rachael Valdez — 336-436-8263 Media@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 9, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 9, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission F

Labcorp Announces Information in Connection with its Spin-off of Fortrea

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Chas Cook — 336-436-5076 Investor@Labcorp.

Labcorp Announces Launch of Fortrea’s Notes Offering in Connection With Anticipated Spinoff

FOR IMMEDIATE RELEASE Labcorp Contacts: Media: Rachael Valdez — 336-436-8263 Media@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 8, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 8, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission F

Labcorp Appoints Dr. Paul Rothman to Board of Directors Health system executive brings three decades of medical enterprise experience to Labcorp

FOR IMMEDIATE RELEASE Labcorp Contacts: Media: Rachael Valdez — 336-436-8263 Media@Labcorp.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 June 5, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact name of registrant as specified in its charter) Delaware 1-11353 13-3757370 (State or othe

SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD Specialized Disclosure Report LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact name of registrant as specified in its charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of (Commission (I.R.S. Employer incorporation or organization) File Number) Identification No.) 358 South Main Street, Burlington, N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 11, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 11, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 4, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 4, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 1-11353 LABORATORY CORPORATION

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 1, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission Fi

LABCORP TO WEBCAST ITS ANNUAL MEETING OF SHAREHOLDERS

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Chas Cook - 336-436-5076 Investor@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 25, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 25, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

Labcorp Announces 2023 First Quarter Results Company Updates Full-Year Guidance

FOR IMMEDIATE RELEASE Contact: Chas Cook (investors) – 336-436-5076 Investor@Labcorp.

LABCORP DECLARES QUARTERLY DIVIDEND

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Chas Cook — 336-436-5076 Investor@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 5, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA H

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 April 5, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103

United States Securities and Exchange Commission Washington, D.C. 20549 NOTICE OF EXEMPT SOLICITATION Pursuant to Rule 14a-103 Name of the Registrant: Laboratory Corporation Holdings of America Name of persons relying on exemption: Tara Health Foundation Address of persons relying on exemption: 47 Kearny Street, San Francisco, CA 94108 Written materials are submitted pursuant to Rule 14a-6(g) (1)

LABCORP TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS ON APRIL 25, 2023

FOR IMMEDIATE RELEASE Labcorp Contacts: Investors: Chas Cook — 336-436-5076 Investor@Labcorp.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 31, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 31, 2023 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission

SEC COURTESY COPY

Proxy Statement & Annual Meeting of ShareholdersDEAR SHAREHOLDER: “In 2022, Labcorp took decisive actions to navigate a challenging operating environment.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the C ommission Only (as permitted by Rule 14a-6(e)(2)) ☒ Def

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro

ENZ / Enzo Biochem, Inc. / Laboratory Corp Of America Holdings - SC 13D Activist Investment

SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Enzo Biochem, Inc. (Name of Issuer) Common Stock, Par Value $0.01 Per Share (Title of Class of Securities) 294100102 (CUSIP Number) Sandra van der Vaart Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary Laboratory Co

Power of Attorney of Kerrii B. Anderson

Exhibit 24.1 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

Power of Attorney of Kathryn E. Wengel

Exhibit 24.9 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart her true and lawful attorney-in-fact and agent, with full power of substitution, for her and in her name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

Power of Attorney of Peter M. Neupert

Exhibit 24.7 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

Amendment No. 1, dated as of January 13, 2023, to the Third Amended and Restated Credit Agreement (originally dated as of April 30, 2021), among the Company, Bank of America, N.A., as administrative agent, and lenders party thereto.

EX-10.12 2 exhibit1012thirdarcreditag.htm EX-10.12 Exhibit 10.12 Execution Version [1]AMENDMENT NO. 1 TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT AMENDMENT NO. 1 dated as of January 13, 2023 (this “Amendment”) to THIRD AMENDED AND RESTATED CREDIT AGREEMENT dated as of April 30, 2021 (the “Credit Agreement”), among LABORATORY CORPORATION OF AMERICA HOLDINGS, a Delaware corporation (the “Borrower

Power of Attorney of Garheng Kong, M.D., Ph.D.

Exhibit 24.6 POWER OF ATTORNEY KNOWN ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Sandra van der Vaart his true and lawful attorney-in-fact and agent, with full power of substitution, for him and in his name, place and stead, in any and all capacities, in connection with the Laboratory Corporation of America Holdings (Corporation) Annual Report on Form 10-K for t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [☒] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 [☐] Transition report pursuant to S

Index UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [☒] Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or [☐] Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number - 1-11353 LABORATORY CORPO